Skip to main content

Genetic Risk Score in Diabetes Associated With Chronic Pancreatitis Versus Type 2 Diabetes Mellitus.

Citation
Goodarzi, M. O., et al. “Genetic Risk Score In Diabetes Associated With Chronic Pancreatitis Versus Type 2 Diabetes Mellitus.”. Clinical And Translational Gastroenterology, p. e00057.
Center UCSD-UCLA University of Alabama at Birmingham
Multicenter
Multicenter
Author Mark O Goodarzi, Tanvi Nagpal, Phil Greer, Jinrui Cui, Yii-Der I Chen, Xiuqing Guo, James S Pankow, Jerome I Rotter, Samer Alkaade, Stephen T Amann, John Baillie, Peter A Banks, Randall E Brand, Darwin L Conwell, Gregory A Cote, Christopher E Forsmark, Timothy B Gardner, Andres Gelrud, Nalini Guda, Jessica LaRusch, Michele D Lewis, Mary E Money, Thiruvengadam Muniraj, Georgios I Papachristou, Joseph Romagnuolo, Bimaljit S Sandhu, Stuart Sherman, Vikesh K Singh, Mel Wilcox, Stephen J Pandol, Walter G Park, Dana K Andersen, Melena D Bellin, Phil A Hart, Dhiraj Yadav, David C Whitcomb, Diabetes and Pancreatic Cancer Consortium for the Study of Chronic Pancreatitis
Abstract

INTRODUCTION: Diabetes mellitus (DM) is a complication of chronic pancreatitis (CP). Whether pancreatogenic diabetes associated with CP-DM represents a discrete pathophysiologic entity from type 2 DM (T2DM) remains uncertain. Addressing this question is needed for development of specific measures to manage CP-DM. We approached this question from a unique standpoint, hypothesizing that if CP-DM and T2DM are separate disorders, they should be genetically distinct. To test this hypothesis, we sought to determine whether a genetic risk score (GRS) based on validated single nucleotide polymorphisms for T2DM could distinguish between groups with CP-DM and T2DM.

METHODS: We used 60 T2DM single nucleotide polymorphisms to construct a weighted GRS in 1,613 subjects from the North American Pancreatitis Study 2 and 2,685 subjects from the Multi-Ethnic Study of Atherosclerosis, all of European origin.

RESULTS: The mean GRS was identical between 321 subjects with CP-DM and 423 subjects with T2DM (66.53 vs 66.42, P = 0.95), and the GRS of both diabetic groups was significantly higher than that of nondiabetic controls (n = 3,554, P < 0.0001). Exploratory analyses attempting to enrich the CP-DM group for pancreatogenic diabetes, such as eliminating diabetes diagnosed before CP, requiring pancreas-specific comorbidities, or removing those with a family history of diabetes, did not improve the ability of the GRS to distinguish between CP-DM and T2DM.

DISCUSSION: Recognizing that we lacked a gold standard to define CP-DM, our study suggests that CP-DM may be a subtype of T2DM, a notion that should be tested in future, large prospective studies.

Year of Publication
2019
Journal
Clinical and translational gastroenterology
Volume
10
Issue
7
Number of Pages
e00057
Date Published
12/2019
ISSN Number
2155-384X
DOI
10.14309/ctg.0000000000000057
Alternate Journal
Clin Transl Gastroenterol
PMID
31232720
PMCID
PMC6708663
Download citation